Related Experiment Video
Updated: Dec 27, 2025
Image-Guided Resection of Glioblastoma and Intracranial Implantation of Therapeutic Stem Cell-seeded Scaffolds
Published on: July 16, 2018
Bone Morphogenetic Protein 4 Targeting Glioma Stem-Like Cells for Malignant Glioma Treatment: Latest Advances and
Sonali Nayak1, Ashorne Mahenthiran1, Yongyong Yang2
1Division of Pediatric Neurosurgery, Ann & Robert H. Lurie Children's Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, IL 60611, USA.
Abstract:
Malignant gliomas are heterogeneous neoplasms. Glioma stem-like cells (GSCs) are undifferentiated and self-renewing cells that develop and maintain these tumors. These cells are the main population that resist current therapies. Genomic and epigenomic analyses has identified various molecular subtypes. Bone morphogenetic protein 4 (BMP4) reduces the number of GSCs through differentiation and induction of apoptosis, thus increasing therapeutic sensitivity. However, the short half-life of BMP4 impedes its clinical application. We previously reviewed BMP4 signaling in central nervous system development and glioma tumorigenesis and its potential as a treatment target in human gliomas. Recent advances in understanding both adult and pediatric malignant gliomas highlight critical roles of BMP4 signaling pathways in the regulation of tumor biology, and indicates its potential as a therapeutic molecule. Furthermore, significant progress has been made on synthesizing BMP4 biocompatible delivery materials, which can bind to and markedly extend BMP4 half-life. Here, we review current research associated with BMP4 in brain tumors, with an emphasis on pediatric malignant gliomas. We also summarize BMP4 delivery strategies, highlighting biocompatible BMP4 binding peptide amphiphile nanostructures as promising novel delivery platforms for treatment of these devastating tumors.
Insights
Bone morphogenetic protein 4 (BMP4) shows promise for treating malignant gliomas by reducing glioma stem-like cells (GSCs). Novel delivery systems are being developed to overcome BMP4
Area of Science:
- Oncology
- Neuroscience
- Biotechnology
Background:
- Malignant gliomas are complex brain tumors driven by therapy-resistant glioma stem-like cells (GSCs).
- Bone morphogenetic protein 4 (BMP4) signaling is crucial in glioma development and presents a therapeutic target.
- Current BMP4 applications are limited by its short biological half-life.
Purpose of the Study:
- To review the role of BMP4 signaling in central nervous system development and glioma tumorigenesis.
- To summarize recent advances in understanding BMP4's therapeutic potential in adult and pediatric gliomas.
- To highlight novel BMP4 delivery strategies for enhanced clinical application.
Main Methods:
- Review of existing literature on BMP4 signaling pathways in brain tumors.
- Analysis of genomic and epigenomic data identifying molecular subtypes of gliomas.
- Examination of advancements in biocompatible materials for BMP4 delivery.
Main Results:
- BMP4 effectively reduces GSCs through differentiation and apoptosis, enhancing therapeutic sensitivity.
- BMP4 signaling pathways play critical roles in regulating tumor biology in both adult and pediatric gliomas.
- Biocompatible BMP4 binding peptide amphiphile nanostructures show potential for extended BMP4 half-life.
Conclusions:
- BMP4 is a promising therapeutic agent for malignant gliomas, particularly pediatric types.
- Overcoming BMP4's short half-life through advanced delivery systems is key to its clinical success.
- Peptide amphiphile nanostructures represent a novel and effective platform for BMP4 delivery in brain tumor treatment.
More Related Videos
10:28Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
Published on: January 10, 2018
09:26Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens
Published on: July 29, 2011